Novo Nordisk | NVO - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
ANI Pharmaceuticals USD 280.15M 5.84M 2026-06
Aurora Cannabis CAD 18.13M 15.07M 2026-03
Bausch Health Companies USD 19.88B 20M 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Canopy Growth CAD 217.12M 7.87M 2026-03
Drreddys Laboratories INR 12.2B 12.07B 2026-03
Eli Lilly USD 47.86B 8.49B 2026-06
GlaxoSmithKline GBP 13.95B 65M 2026-06
Merck USD 51.08B 4.41B 2026-06
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Novartis USD 37.49B 42M 2026-06
Novo Nordisk DKK 121.79B 2.62B 2026-06
Novo Nordisk DKK 18.61B 100.56B 2026-06
Pacira USD 363.12M 4.53M 2026-06
Perrigo USD 3.28B 337.7M 2026-06
Phibro Animal Health USD 597.68M 5.92M 2026-03
Prestige Brands USD 2.02B 1.01B 2026-06
Sanofi EUR 14.65B 806M 2026-06
Supernus Pharmaceuticals USD 400.38M 21.13M 2022-03
Zoetis USD 9.05B 3M 2026-06